Type 1 diabetes is a disorder characterized by the loss of b-cell mass and function. Because b-cells do not spontaneously regenerate sufficiently to correct diabetes, an exogenous source of b-cells could be useful (1). Transplantation of islets from a pancreatic organ donor can restore physiological regulation of blood glucose in human subjects (2) but require management of allo-immunity. Although autologous cells would not address the recurrence of autoimmunity against transplanted b-cells, it obviates the need to suppress allo-immunity. We have recently shown that pluripotent stem cells matched to a subject with type 1 diabetes can be derived from skin cells by somatic cell nuclear transfer (SCNT) (3). Stem cells can also be derived by induction of pluripotency (4), resulting in highly similar cell types with regard to gene expression and DNA methylation (5). However, the functionality of reprogrammed human stem cells has not been sufficiently tested. Notably, nuclear transfer (NT) from adult cells more consistently results in the production of viable mice (6) than in the production from induced pluripotent stem cells (iPSCs) (7), suggesting that reprogrammed cells derived by SCNT are more often fully differentiation competent (8). Reprogramming by NT recapitulates developmental events that occur upon normal fertilization and allows resetting of the epigenome of the
Type 1 diabetes is a disorder characterized by the loss of b-cell mass and function. Because b-cells do not spontaneously regenerate sufficiently to correct diabetes, an exogenous source of b-cells could be useful (1) . Transplantation of islets from a pancreatic organ donor can restore physiological regulation of blood glucose in human subjects (2) but require management of allo-immunity. Although autologous cells would not address the recurrence of autoimmunity against transplanted b-cells, it obviates the need to suppress allo-immunity. We have recently shown that pluripotent stem cells matched to a subject with type 1 diabetes can be derived from skin cells by somatic cell nuclear transfer (SCNT) (3) . Stem cells can also be derived by induction of pluripotency (4) , resulting in highly similar cell types with regard to gene expression and DNA methylation (5) . However, the functionality of reprogrammed human stem cells has not been sufficiently tested. Notably, nuclear transfer (NT) from adult cells more consistently results in the production of viable mice (6) than in the production from induced pluripotent stem cells (iPSCs) (7) , suggesting that reprogrammed cells derived by SCNT are more often fully differentiation competent (8) . Reprogramming by NT recapitulates developmental events that occur upon normal fertilization and allows resetting of the epigenome of the somatic nucleus to an early embryonic state. The generation of iPSCs, in contrast, is performed by ectopic expression of a key set of embryonic transcription factors. Although NT selects for the ability of a cell to advance through embryonic developmental steps, iPSC generation selects for growth in the pluripotent state, not for developmental competence. These differences in the reprogramming process could result in different functional outcomes. However, the differentiation propensities and functional properties of human stem cell lines reprogrammed by SCNT are thus far unknown. The most stringent functional test of human cells is their ability to differentiate into functional b-cells that are able to reverse diabetes in animal models.
Here we assessed whether human pluripotent stem cells derived from skin fibroblasts of a patient with type 1 diabetes by SCNT (1018-NT-ES [embryonic stem] cell) can give rise to differentiated b-cells (1018-NT-b) with qualitative and quantitative physiological performance comparable to naturally occurring b-cells. 1018-NT-b-cells coexpressed C-peptide, pancreatic and duodenal homeobox 1 (PDX1), NK6 homeobox 1 (NKX6.1), as well as musculoaponeurotic fibrosarcoma oncogene family A (MAFA) and showed increased cytosolic calcium and insulin secretion in response to glucose. Upon transplantation, 1018-NT-b-cells protected mice from streptozotocin (STZ)-induced diabetes, and responded to nutrient status by decreasing human C-peptide secretion during fasting and by increasing secretion upon refeeding or glucose administration. In a comparison of NT-ES cell lines and iPSC lines, we found that b-cells could be derived from both cell types, though iPSC lines showed greater variability in differentiation efficiency. Therefore, NT-ES cells matched to a patient with type 1 diabetes could potentially provide a suitable unlimited source of cells for cell replacement to treat diabetes.
RESEARCH DESIGN AND METHODS

Patients and Cell Lines
This study included two human ES (hES) cell lines (INS GFP/W hES and NKX2.1 GFP/W hES) (9,10), three NT-ES cell lines (1018-NT-ES, BJ-NT-ES 5, and BJ-NT-ES 6) (3), and seven human iPSC lines (1158-iPSC, 1159-iPSC, 1023-iPSC, 1018-iPSC A and E, and BJ-iPSC M and O) (3). Further information and quality controls regarding these cell lines is provided in Supplementary Table 1. All human subjects research was reviewed and approved by the Columbia University Institutional Review Board and the Columbia University Embryonic Stem Cell Committee. Refer to the Supplementary Data for additional details.
Cell Culture and b-Cell Differentiation
Pluripotent stem cell lines were maintained on mitomycin Ctreated primary mouse embryonic fibroblasts (catalog #CF-1 MEF IRR; MTI-GlobalStem) and passaged with TrypLE Express (catalog #12605036; Life Technologies) every 5-7 days. Cells were dissociated with TrypLE Express and plated on Matrigel-coated plates in mTeSR Medium (catalog #05850; STEMCELL Technologies) with 10 mmol/L Y27632 (catalog #S1049; Selleckchem). Detailed methods and factors used for differentiation toward b-cells are described in the Supplementary Data. For consistency, b-cell differentiation was performed by one person (L.S.), and comparisons are between differentiation experiments at equal skill levels. All differentiation experiments were included unless a majority of cells died after clustering at the pancreatic progenitor stage. As a quality control for differentiation, part of the cells was stained for stage-specific markers at the definitive endoderm stage, the pancreatic progenitor stage, and the b-cell stage during differentiation.
Static Glucose-Stimulated Insulin Secretion
A total of 10-20 1018-NT-b-cell clusters (;5 3 10 5 cells) and ;100 islet equivalent human islets were collected and preincubated in a 500-mL low-glucose solution for 1 h. Clusters were then sequentially incubated in low-glucose and high-glucose solutions. Incubation in different levels of glucose solutions was repeated once. Supernatants of each condition and protein content were collected and measured using a Mercodia M-Plex ARRAY Chemiluminescent Mercodia Beta Kit. Pictures were taken using a Quansys Q-VIEW Imager and analyzed by Quansys Q-VIEW Software. Refer to the Supplementary Data for additional details.
Dynamic Glucose-Stimulated Insulin Secretion
A microfluidic-based perifusion system was used to determine glucose-stimulated insulin secretion. This experiment was conducted according to previously described methods (11, 12) . Refer to the Supplementary Data for additional details.
Assessment of Insulin Secretion Response to Other Stimuli
Insulin secretion was evaluated in a cell perifusion apparatus with DMEM containing 0.1% BSA, glucose, and test compounds at a flow rate of 1 mL/min as previously described (13) . Refer to the Supplementary Data for additional details.
Immunocytochemistry
Cells at different stages were stained for lineage-specific protein markers during differentiation. Refer to the Supplementary Data for additional details.
Flow Cytometry
The b-cell clusters were dissociated using TrypLE Express into single cells. Cells were fixed with 4% paraformaldehyde for 10 min and followed by permeabilization at 220°C with cold methanol for 10 min. Primary antibodies were added at a dilution of 1:100 in autoMACs Rinsing Solution (catalog #130-091-222; Miltenyi Biotec) containing 0.5% BSA at 4°C for 1 h. Secondary antibodies were added at a dilution of 1:500 at room temperature for 1 h. The cells were filtered with a BD Falcon 12 3 75-mm tube with a cell strainer cap (catalog #352235; BD Biosciences) and subsequently analyzed by flow cytometer. Data were analyzed using FlowJo software. Negative controls were performed by only adding secondary antibodies. 
Transplantation and In Vivo Assay
Eight-to 10-week-old male and female immunocompromised mice (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ [NSG] mice; catalog #005557; The Jackson Laboratory) were used for transplantation. For subcutaneous space transplantation, 40-100 clusters (1-2 million cells with on average 55% C-peptide-positive cells) were collected and settled in a tube with 50-mL of differentiation medium. These clusters were transferred onto gelfoam prewetted with differentiation medium. The clusters and gelfoam were overlaid with 20 mL of Matrigel. The resultant implant constructs were placed in a cell incubator for 5 min and then prewarmed medium were added for further culture until implantation (14, 15) . All animal protocols were approved by the Institutional Animal Care and Use Committee in Columbia University. Refer to the Supplementary Data for additional details.
Statistical Analysis
Data were analyzed by unpaired t test and by one-way ANOVA followed by Tukey's multiple-comparison test (GraphPad Prism 6; GraphPad Software, Inc., La Jolla, CA) and expressed as mean 6 SD. The differences observed were considered statistically significant at the 5% level and were displayed on the figures as follows: *P , 0.05, **P , 0.01, ***P , 0.001, ****P , 0.0001.
RESULTS
An Efficient Protocol for the Derivation of Monohormonal C-Peptide-Positive Cells
We optimized the protocol based on two recently published protocols (16, 17) using INS GFP/W -hES cells (9) . In particular, we tested the induction of pancreatic progenitors expressing both PDX1 and NKX6.1, which are required for the development of mature b-cells (18) . Induction of definitive endoderm in a monolayer culture by the STEMdiff Definitive Endoderm Kit resulted in $95% definitive endoderm cells expressing SOX17, FOXA2, CXCR4, and C-kit on day 4 ( Supplementary Fig. 1A and B). For further differentiation, we applied compounds individually, or in combination, including bone morphogenetic protein 4 (BMP4) inhibitor LDN193189 (LDN), fibroblast growth factor 10, BMP4, epidermal growth factor (EGF), resulting in activation of protein kinase C, TPB (an activator of protein kinase C), sonic hedgehog inhibitor KAAD-cyclopamine (Cyclo), and retinoid acid, which have all been reported to induce pancreatic progenitors (14, 16, 17, 19, 20) . We found that adding EGF for 3 days after 2 days of treatment with Cyclo, LDN, and retinoic acid was the most efficient, with ;30% of cells expressing both PDX1 and NKX6.1 in experiments performed at 80% plating density and in a 96-well plate ( Supplementary Fig. 1C ). Increasing the plating density of ES cells to 100% and differentiation in a 6-well plate led to a further increase (;70% PDX1-and NKX6.1-positive cells can be routinely obtained after adding EGF for 3 days) ( Supplementary Fig. 1D ). LDN was omitted during treatment with EGF, because it resulted in the premature induction of NGN3-positive cells ( Supplementary Fig. 1E ), which is consistent with previous observations that LDN inhibition of BMP4 signaling induces the expression of NGN3 (21) .
We then applied a 3D culture by aggregating the cells in low attachment plates from the pancreatic progenitor stage until the b-cell stage using factors reported in a recently published protocol (Fig. 1A) (17) . Although a monolayer culture also resulted in C-peptide-positive cells (;7%), the 3D culture enabled the generation of much greater numbers of C-peptide-positive cells (.50%) (Supplementary Fig. 2A ). Of these, the majority (70%) were monohormonal, which is shown by the coexpression of NKX6.1 and C-peptide and the absence of glucagon. We also observed that 11% of cells coexpressed C-peptide and glucagon (Supplementary Fig. 2A and B) .
Efficient Differentiation of b-Cells From 1018-NT-ES Cells
Using our optimized protocol, we assessed the ability of NT-ES cells to differentiate into C-peptide-positive cells (Fig. 1A) . Differentiation of 1018-NT-ES cells resulted in the generation of ;95% SOX17-and FOXA2-positive definitive endoderm cells (Fig. 1B and C) , ;97% PDX1-positive cells, and ;80% PDX1 and NKX6.1 coexpressing cells at the pancreatic progenitor stage ( Fig. 1D and E) . At the b-cell stage, on day 27 of differentiation, ;80% of cells in the clusters were PDX1 positive, and up to ;77%, and on average ;55%, of the cells were C-peptide positive (n = 5) (Fig. 1F and L) . Among the C-peptide-positive cells, ;50% coexpressed the b-cell marker NKX6.1 ( Fig. 1G and L) as well as MAFA (Fig. 1H and L) , and they were monohormonal and did not coexpress the other endocrine hormones glucagon or somatostatin (Fig. 1I, K, and L) . The efficient differentiation toward b-cells was also apparent at the mRNA level. Quantitative RT-PCR revealed the absence of OCT4 expression and the upregulation of genes expressed in the pancreatic endocrine lineage: PDX1, FOXA2, NGN3, NKX6.1, SUR1, INS, and GLU ( Supplementary Fig. 3A and Supplementary Table 2 ). Insulin and MAFA expression was lower in 1018-NT-b-cells, although the differences were not significant because of the variation in human islets. Glucagon and NGN3 expression were higher in 1018-NT-b-cell clusters than in human islets, indicating ongoing maturation from endocrine progenitors (Supplementary Fig. 3B ). A total of 2% of C-peptide-positive cells were proliferating, as indicated by the expression of Ki67 (Fig. 1J) . Taken together, these data show that islet-like clusters of endocrine cells, including C-peptide-, NKX6.1-, and MAFA-positive monohormonal b-cells can be efficiently derived from the NT-ES cells of a patient with type 1 diabetes.
We also compared the efficiency of differentiation into C-peptide-positive cells among different cell lines. We used two type 1 diabetes iPSC lines (1018-iPSC A and 1018-iPSC E) that are isogenic to the type 1 diabetes NT-ES cell line (1018-NT-ES) as well as two healthy control iPSC lines (BJ-iPSC M and BJ-iPSC O) with isogenic NT-ES cell lines (BJ-NT-ES 5 and BJ-NT-ES 6). We also studied two hES cell lines (INS GFP/W hESC and NKX2.1 GFP/W hESC), another iPSC line derived from a patient with type 1 diabetes (1158-iPSC), as well as two iPSC lines from healthy subjects (1159-iPSC and 1023-iPSC) (Supplementary Table 1 ). We found that the percentages of C-peptide-positive cells derived from 1018-NT-ES and BJ-NT-ES cell lines were comparable to those obtained from the two hES cell lines (Fig.  1M) . The number of C-peptide-positive cells derived from 1018-iPSC E was significantly lower than that in the isogenic 1018-NT-ES cell line and was also decreased in the BJ-iPSC O compared with that of isogenic BJ-NT-ES cell lines, although it is not statistically significant because of the great variability between individual experiment in BJ-iPSC O (Fig. 1M ). iPSC lines derived from different subjects showed greater variability as well (8-57%) ( Fig. 1M and N) and, on average, a lower capacity to differentiate to C-peptide-positive cells (Fig. 1N) . To determine the time point at which these differences arise, we quantified the percentage of SOX17-positive cells at the definitive endoderm and PDX1-and NKX6.1-positive cells at the pancreatic progenitor stage. We found efficient differentiation to SOX17-and to PDX1-positive cells in all seven cell lines tested ( Fig. 1O and P) . Therefore, differentiation of iPSCs is compromised primarily during the transition from pancreatic progenitors to b-cells.
1018-NT-b-Cell Clusters Secrete Insulin in Response to Physiological Stimuli
To evaluate the functional properties of 1018-NT-b-cell clusters, we first compared hormone production with human islets. The insulin and C-peptide content of 1018-NT-b-cell clusters was approximately sixfold lower than in human islets ( Fig. 2A and B) . The ratio of proinsulin to insulin was elevated in 1018-NT-b-cells, though not statistically significant ( Fig. 2D and E) . We then compared the hormone secretion in a low-glucose medium. 1018-NT-b-cell clusters secreted 21-fold less insulin than human islets, whereas C-peptide secretion was reduced 9-fold ( Fig. 2F and G) . In contrast, the secretion of proinsulin was comparable to human islets, resulting in a high ratio of proinsulin to insulin in 1018-NT-b-cells (Fig. 2I and J) . The production of glucagon showed no significant difference between 1018-NT-b-cell clusters and human islets, whereas the secretion was moderately higher in human islets compared with 1018-NT-b-cell clusters ( Fig. 2C and H) .
To study glucose-stimulated insulin secretion, we exposed 1018-NT-b-cell clusters to different concentrations of glucose and other secretagogues in both a static assay and a perifusion assay. Sequential glucose challenge resulted in a modest increase of insulin secretion (Fig. 2K) . The fold increase in secretion was comparable to that of human islet preparations, though the quality of available human islets was not optimal (16) . In a cell monolayer consisting of 50% C-peptide-positive cells (Supplementary Fig. 4A ), the cytosolic calcium signal increased in response to glucose stimulation in 20% of single cells measured (Fig. 2L) and also increased at the population level (n = 2) ( Supplementary  Fig. 4B and C) . The amplitude of the response was lower than that in human islets (17) . A much greater increase of cytosolic calcium was observed in response to potassium (Fig. 2L) . Consistent with a modest increase in cytosolic calcium, a modest increase in insulin secretion occurred in a perifusion assay in response to glucose stimulation (Fig. 2M) . However, the magnitude of the response was not consistent across different cell preparations (Fig. 2N) . Unlike their muted response to glucose, 1018-NT-b-cell clusters showed increased insulin secretion in response to various other stimuli, including isobutylmethylxanthine, tolbutamide, L-arginine, and KCl ( Fig. 2M and N) . Dithizone staining confirmed that 1018-NT-b-cell clusters contained high levels of zinc (n = 2) (Fig. 2O) , and electron microscopy detected crystallized mature insulin granules (Fig. 2P) , similar to human islets (Fig. 2Q) . A few cells also showed mixed endocrine granules ( Supplementary Fig. 4D ), which is consistent with the persistence of double hormone-positive cells (Fig. 1I) . These functional tests of 1018-NT-b-cells show that despite sharing key features with primary b-cells, functional differences remain in vitro, including reduced insulin content, reduced processing of insulin, and a reduced ability to secrete insulin in response to glucose.
1018-NT-b-Cell Clusters Maintain Normal Blood Glucose Level in Mice With STZ-Induced Diabetes
To determine whether maturation to fully mature b-cells occurred in vivo, we transplanted 1018-NT-b-cell clusters containing 1-2 million cells subcutaneously into immunodeficient mice (n = 22) (14, 15) . Seven batches of 1018-NTb-cell clusters were prepared independently for transplantation. The percentage of C-peptide-positive cells in clusters used for engraftment ranged from 40% to 77%. Because the skin is not a widely used location for the grafting of pancreatic b-cells, we first examined cell survival on day 7 after transplantation (n = 1). C-peptide-positive clusters were detected in the graft (Supplementary Fig. 6A) . Only a few C-peptidepositive cells were undergoing apoptosis, as indicated by TUNEL staining (Supplementary Fig. 6B ). Therefore, subcutaneous transplantation is compatible with viable 1018-NT-b-cells.
Human C-peptide was detected at low levels in mouse serum as early as 1 week after transplantation and increased gradually thereafter. At 1 week after grafting, ;2% of 1018-NT-b-cells were proliferating based on Ki67 staining (Supplementary Fig. 6C ). Mice that remained human C-peptide negative were sacrificed, and no graft was Comparison of insulin, C-peptide, glucagon, proinsulin production, and proinsulin-to-insulin ratio between 1018-NT-b-cell clusters (1018-NT-b) (n = 6 for proinsulin; n = 9 for C-peptide, glucagon, and insulin) and human islets (n = 4). F-J: Insulin, C-peptide, glucagon, proinsulin secretion, and proinsulin-to-insulin ratio upon 2 mmol/L glucose incubation for 30 min were compared between 1018-NT-b-cell clusters (n = 7) and human islets (n = 4). K: Static insulin secretion assay in response to the multiple challenges with 30 min of 2 and 20 mmol/L glucose on 1018-NT-b (n = 4 different batches) and human islet (n = 6 different batches). L: Cytosolic calcium influx signals in response to 2 mmol/L glucose, 20 mmol/L glucose, and 30 mmol/L KCl at single cell level. Insulin secretion in response to a dynamic glucose challenge and KCl challenge using a microfluidic-based perifusion system (M) and other stimuli, including isobutylmethylxanthine, tolbutamide, and L-arginine, in another cell perifusion apparatus (N). O: Dithizone staining of human islets and 1018-NT-b-cell clusters. Inset with size bar (100 mm). Electron microscopy of 1018-NT-b-cells (P) and human islets (Q). Representative insulin granules are indicated by black arrows and magnified. *P , 0.05; ***P , 0.001; ****P , 0.0001.
found (Supplementary Fig. 5A ). Of the 22 mice, 16 were successfully grafted, with detectable C-peptide secretion. Mice transplanted with 1,000 islet equivalent human islets from four preparations under the kidney capsule all secreted human C-peptide (n = 7) (Supplementary Fig. 5B ). Approximately 3 months after transplantation, nine mice from four batches of cell preparation were fasted for 13 h, and the blood glucose and human C-peptide levels were measured before and 3 h after refeeding. Human C-peptide serum levels were increased in eight of nine mice after refeeding, concurrent with an increase in blood glucose levels, indicating that the grafted 1018-NT-b-cells were metabolically responsive (Fig. 3A and B) . The circulating concentrations of human insulin and proinsulin were also measured after 13 h of fasting, and the ratio was comparable to those obtained in mice transplanted with human islets under the kidney capsule (Fig. 3C ). Mice achieving serum human C-peptide concentrations .100 pmol/L (n = 11) were treated with STZ to specifically ablate endogenous mouse b-cells while leaving the transplanted human b-cells intact. Successful ablation was demonstrated in 10 of 11 mice by either mouse C-peptide ELISA (n = 9) (Fig. 3D) or immunostaining of mouse glucagon and C-peptide in pancreata (n = 2) (Supplementary Fig. 5E ). A single mouse with remaining mouse C-peptide (STZ-9) was excluded from further analysis. Of the 10 mice with successful mouse b-cell ablation, 9 maintained normal blood glucose levels, whereas all 3 mice without grafted cells failed to control their blood glucose levels (Fig. 3E) . To evaluate the response of 1018-NT-b-cell grafts to varying blood glucose concentrations, we fasted mice for 13 h followed by glucose injection. Serum human C-peptide levels decreased with blood glucose during fasting and increased more than twofold after the injection of glucose at either 30 or 60 min (Fig. 3F and Supplementary Fig. 5C ). The 1018-NT-b-cell-grafted mice showed clearance of blood glucose at rates comparable to that of mice transplanted with human islets (Fig. 3G and Supplementary Fig. 5D ). Nontransplanted STZ-treated mice failed to clear glucose from the circulation. To determine whether blood glucose was regulated by 1018-NT-b-cells, grafts were surgically removed in two mice. An immediate rise in blood glucose levels was observed (Fig. 3H) . Therefore, 1018-NT-b-cell clusters are responsive to the metabolic state of recipient mice and are adequate for homeostatic regulation of mouse blood glucose levels.
To determine the morphology and composition of the grafts, we sacrificed the mice and performed immunocytochemistry and histology. All examined grafts were contained in the gelfoam scaffold, remained at the site of transplantation and showed no signs of overgrowth ( Fig. 4A and B) . Because we had marked the 1018-NT-ES cells with a constitutively expressed GFP transgene, we could distinguish mouse cells from human cells based on GFP fluorescence (Fig. 4C) . Grafts consisted predominantly of GFP-positive human cells (68% of total grafted area), expressing synaptophysin (42% of the synaptophysinpositive/GFP-positive area of total grafted area), chromogranin A and C-peptide (25% of the C-peptide-positive/GFP-positive area of the total grafted area) (Fig. 4D-F, and J) . Glucagonpositive cells encircled the periphery of C-peptide-positive cell clusters or were mingled within clusters of C-peptidepositive cells (Fig. 4F and G and Supplementary Fig. 6D ), with the latter pattern resembling human islets (22) . Vascularization was also observed in islets indicated by the blood cells (Fig. 4F) . In contrast to in vitro cultures and at 1 week after transplantation ( Supplementary Fig. 6A ), in which up to half of the C-peptide-positive cells also contained glucagon (Fig. 1L) , double hormone-positive cells were rare in vivo 20 weeks after transplantation (,3%; Fig.  4G and K). Grafts were positive for C-peptide, NKX6.1, and MAFA ( Fig. 4H and I) . Eighty-eight percent of C-peptidepositive cells expressed NKX6.1, and 63% of them coexpressed MAFA (Fig. 4K) , which is similar to the human pancreas (23) . Electron microscopy of the grafted cells further confirmed the presence of b-cell granules (Fig. 4L) . We also observed that 3% C-peptide-positive cells were proliferating, as indicated by the coexpression of Ki67 (Fig. 4M) . Besides endocrine tissue, we also found pancreatic ductal structures that express only PDX1 but not NKX6.1 (Fig. 4N and O). Three of 11 examined grafts gave rise to cystic structures, but no teratoma-like growths were found (Supplementary Fig. 6E ). Cystic structures were composed of CK19-positive cells that did not coexpress PDX1 ( Supplementary  Fig. 6F and G) , suggesting that they are of endodermal origin. These results show that 1018-NT-ES-derived C-peptidepositive cells mature to fully functional b-cells in vivo.
DISCUSSION
Here we show that pluripotent stem cells created by SCNT from an individual with long-standing type 1 diabetes can efficiently give rise to physiologically competent b-cells that are sufficient for metabolic homeostasis upon transplantation into mice lacking endogenous b-cells. These results provide a proof of concept for the use of therapeutic "cloning": NT-mediated reprogramming combined with autologous cell therapy (24, 25) .
To efficiently derive b-cells from pluripotent stem cells, we used EGF signaling to induce the generation of NKX6.1-positive cells at the pancreatic progenitor stage, which is consistent with a recently published report (20) . Although the 1018-NT-b-cells expressed markers of mature pancreatic b-cells, a number of differences with human islets were noted in vitro. 1018-NT-b-cells showed proliferation rates comparable to those of human b-cells in the prenatal (17-32 weeks of gestation) pancreas (26) . 1018-NT-b-cells synthesized and secreted less insulin and showed an elevated ratio of proinsulin to insulin. Furthermore, 1018-NT-b-cells showed only a modest increase in cytosolic calcium and a modest increase in insulin secretion in response to high glucose concentrations. These results are consistent with previous observations in hES cell-derived b-cells (16, 17) and are characteristic of human fetal islets (27) (28) (29) . Therefore, this suggests that the differences of 1018-NT-b-cells with pancreatic b-cells represent an earlier developmental stage of differentiation. However, within 2 months after transplantation into mice, no differences to human islets were observed. 1018-NT-b-cell grafts responded to meals and intraperitoneal glucose with the release of insulin. The ratio of serum human proinsulin to insulin was comparable to that of human islets, indicating normal processing. Importantly, we found that the 1018-NT-b-cells could maintain normal blood glucose concentrations in mice lacking native b-cells.
Surprisingly, we found that though both iPSCs and ES cells were able to differentiate to C-peptide-positive cells, iPSCs were more variable in their differentiation efficiency. b-Cells differentiated from iPSCs from subjects with type 1 diabetes were reported previously (4, 30) , but a comparison of differentiation efficiencies was not a topic of these studies. Our observations are consistent with previous reports demonstrating that some iPSC lines are refractory to differentiation and cell maturation, whereas others differentiate with an efficiency similar to ES cells (31) . The underlying molecular reasons for these differences in efficiency compared with b-cells are not currently understood and may require molecular analysis in cells at various stages of differentiation rather than in undifferentiated stem cells alone, which show similar molecular profiles (5).
In summary, our results demonstrate that SCNT provides patient-specific cell lines that can be efficiently differentiated to C-peptide-positive cells. When transplanted into mice, these cells formed islet-like structures and showed metabolic phenotypes consistent with their nominal cellular identities. Therefore, NT-ES cells hold great promise for autologous cell replacement for diabetes. Future studies will focus on improving graft function, for example by the addition of autologous vascularized cells (32) . Furthermore, these NT-ES-b-cells provide a tool with which to study the interactions of elements of the type 1 diabetes immune system reconstituted from patient bone marrow (33) with type 1 diabetes-derived b-cells from the same subject.
